21:36 , Jan 26, 2019 |  BioCentury  |  Product Development

Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy. A host of products based on...
23:25 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

In September, Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) reported additional data from 6 patients with moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008) led to a decline in...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Bertilimumab: Preliminary Ph II data

Preliminary data from 3 patients with moderate to extensive bullous pemphigoid in an open-label, U.S. and Israeli Phase II trial showed that 10 mg/kg IV bertilimumab on days 0, 14 and 28 led to a...
07:00 , Sep 12, 2016 |  BioCentury  |  Emerging Company Profile

Age factors

Alkahest Inc. is identifying factors in human plasma that could serve as therapeutics or novel targets used to treat age-related conditions, including Alzheimer's disease. The newco's work stems from the lab of co-founder Tony Wyss-Coray,...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch Date Company Staff cuts Cash Yrs cash pre-cut Cash date 12-mo op loss ended 12/31 1/7/16 Sequenom Inc. (NASDAQ:SQNM) 20% to 390 $76.2 9.65 12/31/15 $7.9 Sequenom restructured to focus on women's health...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

iCo ophthalmic, autoimmune, infectious news

iCo terminated all employees to preserve cash. In 2014, iCo reported that iCo-007 failed in a Phase II trial to treat diabetic macular edema (DME). The company said it has since conducted “an exhaustive search...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began an open-label, Israeli Phase II trial to evaluate 2 doses of IV bertilimumab given 14 days apart in 10 patients with moderate to severe bullous pemphigoid. Patients will also receive oral prednisone....
07:00 , Sep 29, 2014 |  BC Week In Review  |  Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began a double blind, placebo-controlled, Israeli Phase II trial to evaluate 3 doses of 10 mg/kg IV bertilimumab given 2 weeks apart in about 42 adults with UC. Immune Pharmaceuticals has rights to...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Bertilimumab: Phase II started

Immune Pharmaceuticals began patient screening in an open-label Phase II trial to evaluate 2 doses of 10 mg/kg IV bertilimumab given 14 days apart in 10-15 patients with moderate to severe bullous pemphigoid. Patients will...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Clinical News

Bertilimumab: Phase II start

In April, Immune Pharmaceuticals will begin a double-blind, placebo-controlled, international Phase II trial to evaluate 7 mg/kg IV bertilimumab every other week for 4 weeks in about 90 patients with active moderate to severe UC....